menu
    • menu

    Company profile for Alumis

    NEW Drugs in Dev: 3
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Alumis is dedicated to transforming the lives of patients grappling with immune diseases through a precision-oriented approach. Our objective is to enhance patient lives substantially by replacing broad immunosuppression with targeted therapies. Our existence is centered around addressing the specific needs of these patients. We are at the forefront of pioneering a precision approach that utilizes insights derived from powerfu...
    Alumis is dedicated to transforming the lives of patients grappling with immune diseases through a precision-oriented approach. Our objective is to enhance patient lives substantially by replacing broad immunosuppression with targeted therapies. Our existence is centered around addressing the specific needs of these patients. We are at the forefront of pioneering a precision approach that utilizes insights derived from powerful data analytics to select the right target, molecule, indication, patient, and endpoint, ultimately optimizing outcomes for patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AlumisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    611 Gateway Blvd, Suite 820, South San Francisco, California 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.alumis.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/alumis-co/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/_Alumis

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CGT Asia

    Not Confirmed

    envelop Contact Supplier

    CGT Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi, Incyte, Roivant, Alumis Advance In Skin Disease Research
    Sanofi, Incyte, Roivant, Alumis Advance In Skin Disease Research

    31 Mar 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/aad-2026-sanofi-incyte-roivant-and-alumis-make-headway-into-skin-diseases

    BIOSPACE
    31 Mar 2026
    Share Share
    Alumis' Envudeucitinib Succeeds in Phase 3 Psoriasis Trial
    Alumis' Envudeucitinib Succeeds in Phase 3 Psoriasis Trial

    28 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/28/3264196/0/en/Alumis-Envudeucitinib-Delivers-Early-and-Robust-Improvements-in-Skin-Clearance-Quality-of-Life-and-Psoriasis-Symptoms-in-Two-Phase-3-Trials-Underscoring-Its-Potential-as-a-Leading-.html

    GLOBENEWSWIRE
    28 Mar 2026
    Share Share
    Alumis Reveals 2025 Financials And Recent Milestones
    Alumis Reveals 2025 Financials And Recent Milestones

    19 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/19/3259420/0/en/Alumis-Reports-Year-End-2025-Financial-Results-and-Highlights-Recent-Achievements.html

    GLOBENEWSWIRE
    19 Mar 2026
    Share Share
    Alumis Unveils Phase 3 Envudeucitinib Psoriasis Data at 2026
    Alumis Unveils Phase 3 Envudeucitinib Psoriasis Data at 2026

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258105/0/en/Alumis-Announces-Late-Breaker-Oral-Presentation-of-Phase-3-Data-for-Envudeucitinib-in-Moderate-to-Severe-Plaque-Psoriasis-at-2026-American-Academy-of-Dermatology-Annual-Meeting.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    Alumis To Present At Global Healthcare Conference
    Alumis To Present At Global Healthcare Conference

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247361/0/en/Alumis-to-Present-at-the-Leerink-Partners-Global-Healthcare-Conference.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Alumis To Participate In Upcoming February Investor Conferences
    Alumis To Participate In Upcoming February Investor Conferences

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232969/0/en/Alumis-to-Participate-in-Upcoming-February-Investor-Conferences.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search